Metabolic Health Matters More than Weight in Cancer Prevention

The relationship between obesity and cancer has long been established,¹ but a critical question remains: Is it weight itself or metabolic dysfunction that drives cancer risk? For decades, body mass index (BMI) has served as the primary metric for assessing obesity-related health risks. However, this one-dimensional approach fails to capture the metabolic heterogeneity within weight categories.² The concept of ‘metabolically healthy obesity’ (MHO) and ‘metabolically unhealthy normal weight’ has emerged to address this limitation, recognizing that individuals with similar body weights can exhibit vastly different cardiometabolic profiles and health outcomes.^3,4

The prospective cohort study in this issue of Journal of Obesity & Metabolic Syndrome by Golzarand et al.⁵ includes 18 years of longitudinal evidence that provide a compelling challenge to the conventional understanding of the obesity-cancer connection. Leveraging data from 11,445 participants in the Tehran Lipid and Glucose Study, the study demonstrates that metabolic dysfunction—independent of body weight—is a critical determinant of cancer risk.⁵ Their findings reveal a nuanced picture: metabolically unhealthy normal-weight/overweight individuals showed a 37% increased cancer risk (hazard ratio [HR], 1.37; 95% confidence interval [CI], 1.04 to 1.82), while those with metabolically unhealthy obesity exhibited an 84% elevated risk (HR, 1.84; 95% CI, 1.21 to 2.79) compared to metabolically healthy normal-weight counterparts. This suggests that the metabolic milieu, characterized by insulin resistance, dyslipidemia, hypertension, and chronic inflammation, may be more oncogenic than adiposity per se.¹

Sex-specific analysis reveals particularly concerning findings for breast cancer. Women with MHO demonstrated a 3.6-fold increased risk (HR, 3.60; 95% CI, 1.34 to 9.60), while those with metabolically unhealthy obesity showed a 4.7-fold increase (HR, 4.69; 95% CI, 1.96 to 11.20), compared to metabolically healthy normal-weight women.⁵ Notably, even MHO conferred substantial breast cancer risk, suggesting that in this particular malignancy, adiposity itself—likely through increased aromatase activity in adipose tissue leading to elevated estrogen levels—plays a significant independent role beyond metabolic dysfunction.^6,7

The biological mechanisms linking metabolic dysfunction to cancer are multifactorial. Insulin resistance leads to chronic hyperinsulinemia, which can promote cellular proliferation through insulin and insulin-like growth factor-1 signaling pathways.¹ Chronic low-grade inflammation creates a tumor-permissive microenvironment through pro-inflammatory cytokines.⁸ Additionally, adipokine dysregulation—with elevated leptin and reduced adiponectin—further contributes to oncogenesis.⁹ These findings align with recent meta-analyses demonstrating that metabolic syndrome significantly increases breast cancer risk.¹⁰

Interestingly, Golzarand et al.’s study⁵ found that transitions between metabolic phenotypes over time did not significantly alter cancer risk. This counterintuitive finding raises important questions: Is there a ‘point of no return’ where metabolic damage becomes irreversible? Or does the duration of metabolic dysfunction matter more than its presence at a single time point? While these questions warrant further investigation, they underscore the importance of early prevention and sustained metabolic health throughout life.

These findings compel us to move beyond BMI-based risk stratification in cancer prevention.^3,11 Clinicians should routinely assess metabolic health parameters—blood pressure, lipid profiles, glucose homeostasis, and inflammatory markers—even in normal-weight individuals. Furthermore, cancer prevention strategies must shift focus from weight loss alone to metabolic health optimization. This includes dietary interventions emphasizing metabolic health markers rather than caloric restriction alone, physical activity that improves insulin sensitivity and reduces inflammation, and pharmacological interventions for metabolic syndrome components when lifestyle modifications are insufficient. Regular screening for early detection of metabolic dysfunction should become standard practice.

While this study provides valuable insights from 18 years of follow-up, several questions remain. The study population from Tehran may not be fully generalizable to populations with different genetic backgrounds and environmental exposures. Site-specific analyses for different cancer types with larger sample sizes would be valuable. Additionally, more granular assessment of metabolic trajectories and the timing of interventions could help identify critical windows for cancer prevention.

As we move forward, cancer prevention strategies must evolve to incorporate comprehensive metabolic assessments. The identification and treatment of metabolically unhealthy phenotypes—regardless of body weight—represents a promising frontier in reducing cancer burden. For the millions worldwide living with metabolic syndrome, these findings offer both a warning and an opportunity: metabolic health is modifiable, and its optimization may be one of our most powerful tools in cancer prevention.

The message is clear: in the fight against cancer, metabolic health matters—perhaps more than previously recognized.